Epidemiology of SARS-CoV-2 during the first three waves in Scotland: a national record linkage study.
COVID-19
DEATH
EPIDEMIOLOGIC MEASUREMENTS
HEALTH POLICY
PUBLIC HEALTH
Journal
Journal of epidemiology and community health
ISSN: 1470-2738
Titre abrégé: J Epidemiol Community Health
Pays: England
ID NLM: 7909766
Informations de publication
Date de publication:
08 Nov 2022
08 Nov 2022
Historique:
received:
07
06
2022
accepted:
14
10
2022
entrez:
8
11
2022
pubmed:
9
11
2022
medline:
9
11
2022
Statut:
aheadofprint
Résumé
The early COVID-19 pandemic in Scotland-defined as the era before widespread access to vaccination and monoclonal antibody treatment-can be characterised into three distinct waves: March-July 2020, July 2020-April 2021 and May-August 2021. Each wave was met with various societal restrictions in an effort to reduce disease transmission and associated morbidity and mortality. Understanding the epidemiology of infections during these waves can provide valuable insights into future pandemic planning. Scottish RT-PCR testing data reported up until 8 August 2021, the day prior to most restrictions being lifted in Scotland, were included. Demographic characteristics including age, sex and social deprivation associated with transmission, morbidity and mortality were compared across waves. A case-control analysis for each wave was then modelled to further compare risk factors associated with death over time. Of the 349 904 reported cases, there were 18 099, 197 251 and 134 554 in waves 1, 2 and 3, respectively. Hospitalisations, intensive care unit admissions and deaths appeared highest in wave 2, though risk factors associated with COVID-19 death remained similar across the waves. Higher deprivation and certain comorbidities were associated with higher deaths in all waves. Despite the higher number of cases reported in waves 2 and 3, case fatality rates were lower: likely a combination of improved detection of infections in younger age groups, introduction of social measures and vaccination. Higher social deprivation and comorbidities resulted in higher deaths for all waves.
Sections du résumé
BACKGROUND
BACKGROUND
The early COVID-19 pandemic in Scotland-defined as the era before widespread access to vaccination and monoclonal antibody treatment-can be characterised into three distinct waves: March-July 2020, July 2020-April 2021 and May-August 2021. Each wave was met with various societal restrictions in an effort to reduce disease transmission and associated morbidity and mortality. Understanding the epidemiology of infections during these waves can provide valuable insights into future pandemic planning.
METHODS
METHODS
Scottish RT-PCR testing data reported up until 8 August 2021, the day prior to most restrictions being lifted in Scotland, were included. Demographic characteristics including age, sex and social deprivation associated with transmission, morbidity and mortality were compared across waves. A case-control analysis for each wave was then modelled to further compare risk factors associated with death over time.
RESULTS
RESULTS
Of the 349 904 reported cases, there were 18 099, 197 251 and 134 554 in waves 1, 2 and 3, respectively. Hospitalisations, intensive care unit admissions and deaths appeared highest in wave 2, though risk factors associated with COVID-19 death remained similar across the waves. Higher deprivation and certain comorbidities were associated with higher deaths in all waves.
CONCLUSIONS
CONCLUSIONS
Despite the higher number of cases reported in waves 2 and 3, case fatality rates were lower: likely a combination of improved detection of infections in younger age groups, introduction of social measures and vaccination. Higher social deprivation and comorbidities resulted in higher deaths for all waves.
Identifiants
pubmed: 36347597
pii: jech-2022-219367
doi: 10.1136/jech-2022-219367
pmc: PMC9763220
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Heart. 2015 Aug;101(15):1182-9
pubmed: 26041770
BMJ Glob Health. 2020 Sep;5(9):
pubmed: 32912856
Pediatr Crit Care Med. 2012 Jul;13(4):375-80
pubmed: 22198811
Euro Surveill. 2021 Aug;26(31):
pubmed: 34355691
Age Ageing. 2021 Sep 11;50(5):1482-1492
pubmed: 33963849
J Infect. 2021 Apr;82(4):84-123
pubmed: 33152376
Lancet Digit Health. 2021 Sep;3(9):e539-e541
pubmed: 34384736
Emerg Infect Dis. 2006 Jan;12(1):15-22
pubmed: 16494711
Transbound Emerg Dis. 2021 Mar;68(2):213-215
pubmed: 32892500
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
J Epidemiol Community Health. 2020 Nov;74(11):964-968
pubmed: 32535550
BMJ Open. 2021 Jan 17;11(1):e042140
pubmed: 33455936
BMJ. 2021 Feb 22;372:n523
pubmed: 33619037
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet. 2021 Jun 26;397(10293):2461-2462
pubmed: 34139198
Caspian J Intern Med. 2020 Fall;11(Suppl 1):544-550
pubmed: 33425273
Lancet Reg Health Eur. 2021 Feb;1:100005
pubmed: 34173618
JAMA. 2020 Sep 8;324(10):998-1000
pubmed: 32789492
PLoS One. 2020 Nov 5;15(11):e0241824
pubmed: 33152008
Thorax. 2021 Jul;76(7):714-722
pubmed: 33402392
J R Soc Med. 2022 Jan;115(1):22-30
pubmed: 34672832
Lancet Infect Dis. 2022 Mar;22(3):357-366
pubmed: 34562375
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
BMC Med. 2020 May 29;18(1):160
pubmed: 32466757
Lancet. 2003 Oct 25;362(9393):1353-8
pubmed: 14585636
PLoS Med. 2020 Oct 20;17(10):e1003374
pubmed: 33079969
JAMA Netw Open. 2021 Mar 1;4(3):e211085
pubmed: 33688964
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427